Has Gloria von Geldern, MD received payments from drug or device companies?

Yes. Drug and device makers reported $1,565 in general payments to Gloria von Geldern, MD across 5 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Gloria von Geldern, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Gloria von Geldern, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Gloria von Geldern, MD

Neurology · Seattle, WANPI 1356533723

Payments from drug & device makers

What this record shows

This record is dominated by travel and lodging: $1,058 of the $1,565 with a category attached, or 67.6%. Novartis accounts for 80.8% of it on its own, with 1 other manufacturer making up the rest.

$1,565in general payments, 2019–2025

Across 5 payments — averaging $312.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Novartis$1K
Biogen$300

$439,084in research payments, 2019–2025

Across 8 payments — averaging $54,886 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

Novartis$439K

What the payments were for

Consulting fees$30019%
Travel & lodging$1,05868%
Food & beverage$20613%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Novartis	3	$1,265
Biogen	2	$300

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

TYSABRI$300

How this compares

$1,565 in reported general payments places this provider in the 70th percentile of 418 neurology providers in Washington.

See all neurology providers in Washington →

Medicare billing

Part B allowed, 2024

$27,043

Medicare patients

Services billed

320

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
CopaxoneGlatiramer Acetate	41	$210,162
Avonex Pen (4 Pack)Interferon Beta-1a	14	$128,360
AubagioTeriflunomide	12	$110,352
VumerityDiroximel Fumarate	12	$103,600
Kesimpta PenOfatumumab	11	$88,809
AmpyraDalfampridine	17	$67,935
Gamunex-CImmune Globul G/Gly/Iga Avg 46	34	$58,885
GlatopaGlatiramer Acetate	26	$54,105
Dalfampridine ErDalfampridine	62	$27,984
Dimethyl Fumarate	29	$19,724
Baclofen	136	$3,283
Modafinil	70	$2,736
Gabapentin	93	$2,656
Duloxetine Hcl	73	$1,816
Tizanidine Hcl	53	$1,090

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

Company	Paid to this provider	Part D cost of their drugs
BiogenVumerity	$300	$103,60012 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 418 neurology providers in Washington.

Other neurology in Seattle

Pavle RepovicSeattle$1.1M
Nathaniel WatsonSeattle$486K
Christyn EdmundsonSeattle$318K
Pravin KhemaniSeattle$194K
Mariko KitaSeattle$186K
Michael RosenbloomSeattle$179K
Michael WeissSeattle$103K
Sylvia LucasSeattle$90K
Shuvro RoySeattle$46K
Lucas McCarthySeattle$40K

See the full list for Washington →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →